Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Earnings Results, Misses Expectations By $0.36 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36), Zacks reports. The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The firm’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.15 earnings per share. Alnylam Pharmaceuticals updated its FY 2024 guidance to EPS.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $7.32 during mid-day trading on Friday, hitting $273.91. The stock had a trading volume of 866,294 shares, compared to its average volume of 871,240. The firm has a market cap of $35.16 billion, a PE ratio of -104.55 and a beta of 0.39. The company has a 50 day moving average of $274.61 and a two-hundred day moving average of $226.42. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on ALNY shares. Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday. Bank of America upped their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup upped their price target on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Scotiabank lifted their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday. Six research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $294.50.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.